DNA vaccines against human immunodeficiency virus type 1

Immunological Reviews

Volumn 199, Issue , 2004, Pages 144-155

  Estcourt, Marie J ^a   McMichael, Andrew J ^a   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVAX; CD8 ANTIGEN; DNA VACCINE; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; NEF PROTEIN; NEUTRALIZING ANTIBODY; PLASMID DNA; POL PROTEIN; PROSTAGLANDIN A2; PROTEIN P25; PROTEINASE; VIRUS ENVELOPE PROTEIN; VPR PROTEIN;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; INTEGRATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; HIV-1; HUMANS; PLASMIDS; VACCINES, DNA;

EID: 2942519878     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00151.x     Document Type: Review

References (128)

1. UNAIDS. AIDS Epidemic Update: December, 2001. 2001, UNAIDS/WHO: Geneva.
2. Klausner RD, et al. Medicine. The need for a global HIV vaccine enterprise. Science 2003;300:2036-2039.
3. Binley JM, et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000;74:627-643.
4. Earl PL, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
5. Earl PL, Broder CC, Doms RW, Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997;71:2674-2684.
6. Earl PL, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001;75:645-653.
7. Yang X, et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000;74:4746-4754.
8. Rossio JL, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998;72:7992-8001.
9. Kang CY, Luo L, Wainberg MA, Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol Chem 1999;380:353-364.
10. Paul NL, et al. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses 1993;9:963-970.
11. Ourmanov I, Bilska M, Hirsch VM, Montefiori DC. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol 2000;74:2960-2965.
12. Wyatt R, et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
13. Jeffs SA, et al. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol 1996;77:1403-1410.
14. Barnett SW, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001;75:5526-5540.
15. Binley JM, et al. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses 1998;14:191-198.
16. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4:679-684.
17. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion-competent vaccines, broad neutralization of primary isolates of HIV. Science 1999;283:357-362.
18. Kolchinsky P, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999;73:8120-8126.
19. LaBranche CC, et al. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 1999;73:10310-10319.
20. Ditzel HJ, et al. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol 1995;154:893-906.
21. Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 1994;68:5854-5862.
22. Fouts TR, et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 2000;74:11427-11436.
23. Johnson DC, Hubert MT. Direct egress of animal viruses promotes cell-to-cell spread. J Virol 2002;76:1-8.
24. Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001;75:5721-5729.
25. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002;14:495-502.
26. Hanke T. Development of prophylactic AIDS vaccines: the current state of affairs. Curr Opin Mol Ther 2003;5:25-33.
27. + lymphocytes. Science 1999;283:857-860.
28. Jin X, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
29. Rowland-Jones SL, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
30. Rowland-Jones SL, et al. Cytotoxic T cell responses to multiple conserved epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.
31. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611.
32. Rowland-Jones SL, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
33. Pinto LA, et al. Env-specific cytotoxic T lymphocytes in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995;96:867-876.
34. Zhang C, Cui Y, Houston S, Chang LJ. Protective immunity to HIV-1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals. Proc Natl Acad Sci USA 1996;93:14720-14725.
35. Wagner L, et al. Beta-chemokines are released from HIV-1-specific cytolytic T cell granules complexed to proteoglycans. Nature 1998;391:908-911.
36. Price DA, et al. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998;8:355-358.
37. Stanford SA, et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999;96:1030-1035.
38. McMichael A. T cell responses and viral escape. Cell 1998;93:673-676.
39. Kwong PD, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.
40. Klenerman P, Wu Y, Phillips RHIV. current opinion in escapology. Curr Opin Microbiol 2002;5:408-413.
41. O'Connor DH, Allen TM, Watkins DI. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol 2002;21:659-664.
42. Barouch DH, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-339.
43. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996;2:1122-1128.
44. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997;186:1481-1486.
45. + T cells after gene gun immunization. J Exp Med 1998;188:1075-1082.
46. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996;89:59-67.
47. Fu TM, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-371.
48. Melief CJ. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-2654.
49. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
50. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology 2000;43:331-338.
51. Smith HA, Klinman DM. The regulation of DNA vaccines. Curr Opin Biotechnol 2001;12:299-303.
52. Martin T, et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999;10:759-768.
53. Robertson JS, Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Mol Biotechnol 2001;17:143-149.
54. Ledwith BJ, et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000;43:258-272.
55. Manam S, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000;43:273-281.
56. Hanke T, et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA) -based HIV vaccines for Kenya. Vaccine 2002;21:108-114.
57. Dandolos E, Roumeliotou-Karayannis A, Richardson SC, Papaevangelou G. Safety and immunogenicity of a recombinant hepatitis B vaccine. J Med Virol 1985;17:57-62.
58. Mincheff M, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000;38:208-217.
59. Conry RM, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8:2782-2787.
60. Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur J Clin Microbiol Infect Dis 2001;20:800-803.
61. MacGregor RR, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92-100.
62. Moorthy VS, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003;21:1995-2002.
63. Gilbert PB, et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 2003;21:2933-2947.
64. Mwau M, et al. An HIV-1 clade A vaccine in clinical trials: Stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004;85:911-919.
65. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995;377:632-634.
66. Singh RA, Wu L, Barry MA. Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J Immunol 2002;168:379-391.
67. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002;2:461-471.
68. Cao H, et al. Cytotoxic T lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol 1997;71:8615-8623.
69. Ferrari G, et al. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood 1997;90:2406-2416.
70. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol 2001;2:473-475.
71. Burrows SR, Rodda SJ, Suhrbier A, Geysen HM, Moss DJ. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur J Immunol 1992;22:191-195.
72. + T cell approach feasible? Nat Rev Immunol 2002;2:283-291.
73. + T lymphocytes. Nature 2003;421:852-856.
74. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999;17:51-88.
75. Wilson CC, et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to Multiple conserved epitopes in HIV-1. J Immunol 2003;171:5611-5623.
76. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998;187:1647-1657.
77. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
78. Nkolola JP, et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther (in press)
79. + T-cell memory determined by clonal burst size. Nature 1994;369:652-654.
80. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987;15: 8125-8148.
81. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72:1497-1503.
82. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;6:951-955.
83. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
84. Davenport MP, Fazou C, McMichael AJ, Callan MF. Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J Immunol 2002;168:3309-3317.
85. Yankauckas MA, et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993;12:771-776.
86. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application and otpimization. Annu Rev Immunol 2000;18:927-974.
87. Williams SG, Cranenburgh RM, Weiss AME, Wrighton CJ, Sherratt DJ, Hanak JAJ. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 1998;26:2120-2124.
88. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002;71:813-820.
89. Hemmi H, Kaisho T, Takeda K, Akira S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003;170:3059-3064.
90. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
91. Leifer CA, Verthelyi D, Klinman DM. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 2003;26:313-319.
92. Zhang L, Widera G, Bleecher S, Zaharoff DA, Mossop B, Rabussay D. Accelerated immune response to DNA vaccines. DNA Cell Biol 2003;22:815-822.
93. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000;18:2779-2788.
94. Widera G, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-4640.
95. Raviprakash K, et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003;315:345-352.
96. Haynes JR, Fuller DH, McCabe D, Swain WF, Widera G. Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Deliv Rev 1996;21:3-18.
97. Koshkina NV, Agoulnik IY, Melton SL, Densmore CL, Knight V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes, optimization of pulmonary delivery and retention. Mol Ther 2003;8:249-254.
98. Choi MJ, Maibach HI. Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 2003;16:271-282.
99. Shata MT, Stevceva L, Agwale S, Lewis GL, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000;6:66-71.
100. Seaman MS, et al. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 2004;78:205-215.
101. Glansbeek HL, et al. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. J Gen Virol 2002;83:1-10.
102. Xin KQ, et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999;92:90-96.
103. Barouch DH, Letvin NL. DNA vaccination for HIV-1 and SIV. Intervirology 2000;43:282-287.
104. Barouch DH, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
105. Barnett SW, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 subunit. Vaccine 1997;15:869-973.
106. Letvin NL, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Nat Acad Sci USA 1997;94:9378-9383.
107. Leong KH, Ramsay AJ, Ramshaw IA, Morin J, Robinson HL, Boyle DB. Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowl poxvirus. In: Brown, F, Chanock, R, Ginsberg, H, eds. Vaccines 95. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1995:327-331.
108. Ramsay AJ, Leong KH, Ramshaw IA. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol 1997;75:382-388.
109. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-1601.
110. Hanke T, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
111. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
112. Hanke T, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532.
113. Allen TM, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000;164:4968-4978.
114. Robinson HL, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526-534.
115. Amara RR, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
116. Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Ann NY Acad Sci 1995;772:198-208.
117. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 2002;14:31-37.
118. Sedlik C, et al. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 2000;74:5769-5775.
119. Slifla MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2001;2:711-717.
120. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184:485-492.
121. Dutoit V, et al. Heterogeneous T-cell response to MAGE-A10 (254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001;61:5850-5856.
122. Zeh HJ, 111, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
123. Boyer JD, et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000;181:476-483.
124. Mwau M, McMichael AJ, Hanke T. design and validation of an ELISPOT assay for use in clinical trials of candidate HIV Vaccines. AIDS Res Hum Retroviruses 2002;18:611-618.
125. Boyer JD, et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol 1999;90:100-107.
126. Ugen KE, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in human. Vaccine 1998;16:1818-1821.
127. Currier JR, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-172.
128. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.